MedTrace Logo

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

NCT03426605 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-05-03

Study results available
· View outcomes & findings →

Summary

A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia

Conditions

Interventions

DRUG

Open Label LAM-003

LAM-003

Sponsors & Collaborators

  • OrphAI Therapeutics

    lead INDUSTRY

Principal Investigators

  • Langdon Miller, M.D. · AI Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-16
Primary Completion
2020-02-20
Completion
2020-10-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426605 on ClinicalTrials.gov